We help our clients and their customers successfully deploy,
protect, maintain, retire and re-use technology.


The world is witnessing explosive growth in the number of connected devices, and in the power and complexity of mobile computing platforms. This is resulting in an increasing need for sophisticated technology- and user support. Regenersis addresses those needs with a growing portfolio of software-rich services building on a strong heritage of repair operations, customer service and data erasure management.

By combining our capabilities in innovative ways, tailored to individual client requirements, we deliver unique service propositions that reinforce trust in our client’s brands and create value for our business partners and shareholders.


Technology Life Cycle Services

Our international network of repair centres provides product repair, refurbishment, parts management and logistics services for mobile, IT, home entertainment and B2B infrastructure product vendors; and their sales channels, insurers, and end users. Our technically-advanced repair capabilities enjoy a solid reputation with our TMT sector clients, combining service excellence with continuous gains in cost efficiency.

Our industry-leading fault diagnostics and issue resolution technologies include the In-Field Tester for set top boxes, and our SmartChk applications suite for smartphones. These advanced diagnostic platforms improve consumer satisfaction with their devices and materially reduce the incidence and cost of product returns for our clients.

In partnership with leading insurers, our Digital Care operations deliver innovative product insurance and extended warranty programmes for our clients, protecting customers’ investments in mobile technology products.

Our Recommerce division helps manufacturers and retailers to launch products and attract new customers through upgrade and buy-back programmes.

Blancco is the global leader in data erasure management (DEM). Blancco software provides comprehensive data erasure for every type of electronic and magnetic storage media, ranging from portable flash drives and mobile phone memory to solid state drives, networked storage, virtual drives and cloud storage. Blancco DEM is a vital part of any organisation’s security infrastructure, underpinning robust data retention policies and ensuring compliance with international data protection regulations.

Regenersis around the world

Our clients increasingly seek partners who can deliver cost-effective and innovative technology life cycle services on a global basis. Since 2011, Regenersis has expanded its geographical footprint from five countries to 16. With the acquisition of Blancco in April 2014, this increased to 22 countries.



http://www.regenersis.com/about-us








Final Results

http://www.moneyam.com/action/news/showArticle?id=4451090

Financial Highlights

·
Group revenue increased by 13% to £139.9 million (2011: £123.8 million)

·
Headline operating profit(*) increased by 24% to £7.8 million (2011: £6.3 million)

·
Operating cash flow improved to £4.9 million (2011: £2.4 million).

·
Further Improvement in headline operating margin to 5.5% (2011: 5.1%)

·
Net debt reduced to £2.9 million (2011: £3.8 million)

·
Banking facility extended from £15 million to £23.25 million for the period to October 2015, to support further organic investment and incremental M&A activity

·
First dividend payment since 2007 - recommended final dividend of 1.1 pence per ordinary share

Even put an ''S'' on the end of development to no avail. lol

Got it in my e-mail.

Might be best to go direct to the site.

Usually do a good note on companys.

See if that works

Regenersis CFO tops up stake as results impress

Tue, 24 September 2013


Jog Dhody, the Chief Financial Officer of Regenersis, on Tuesday acquired 39,000 ordinary shares in the outsourcing partner on the same day it posted "a strong financial performance and good growth" for the year ended June 30th.

Dhody bought the shares a price of 255p per share, spending a total of £99,450. Following the acquisition, he has a beneficial interest of 355,285 shares, representing 0.7% of the company's issued share capital.

In the 12 months to the end of June, the company's revenue increased to £179.7m (2012: £139.9m), while headline operating profit increased to £9.5m (2012: £7.8m) and pre-tax profit of £5.67m (2012: £1.68m).

Net debt fell to £1.9m (FY 2012: £2.9m and HY 2013: £7.7m).

The group recommended a final dividend of 1.83p per ordinary share (2012: 1.1p per share), giving a total dividend for the year of 2.5p per ordinary share (2012: 1.1p) - up 127%.

Looks good for us DC.

We know are onions .......LOL.

lol

I put three threads together for Regenisis, Cranware and Clinigen. Got two right so far. Cranware looked promising but to date has underperformed and do not currently hold. The other two are going fantastic.

Try:

Regenersis - Repaired and Prepared - 25 Sept 2013

Director Deals - Regenersis PLC (RGS)

Tom Russell, Non Executive Director, bought 38,000 shares in the company on the 25th September 2013 at a price of 264.00p. The Director now holds 38,000 shares.

Cheers ExecLine appreciated.

DC .......Halifax wont be on my tail mate,Ive had him filtered for over a year.

He must be costing moneyam a fortune. Investors must be walking away from this site. Always negative. Sounds like his previous employment was a school games teacher or in the army.

dc or perhaps even a police officer....... behave girls!!

I thought so. :-))

DC just filter him. hes a waste of space.

IC today - Regenersis charging ahead.

Chief executive Matthew Peacock is confident the group can achieve double-digit revenue and earnings growth for the next three years.


Regenersis is becoming the dominant player in the market and also boasts a strong balance sheet. They still trade on 14 times forecast earnings. That looks too modest given the potential for further growth and market share wins.

A buy in this weeks Shares - Directors buying sends vote of confidence. Stock broker Panmure Gordon increased its price target from 240p to 302p on the back of the results.

Just bought these back and may be taking a big gamble with the ongoing US problem. My first purchase in about 2weeks.

Any decent company seems to be holding up well in these uncertain market times.

Sp climbing hard since 1 sept.

Going well, itl do me.